Who
Garry Arthur Neil
Director
Company insider
Files Form 4 as: Director, Celldex Therapeutics; Chief Executive Officer, Avalo Therapeutics; Director, Zura Bio; Director, Arena Pharmaceuticals; Chief Scientific Officer, Aevi Genomic Medicine; Director, Gtx Inc /de/.
In numbers
- Trades disclosed
- 94
- Buys
- 10
- Sells
- 0
- Bought
- $611K
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 13 Sep 2013
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,200 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,200 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —64,866 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $304K21,892 at $13.89 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,866 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,866 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —64,866 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $304K21,892 at $13.89 | filing |
| 26 Feb 2026filed 2 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,867 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —64,867 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $150K17,787 at $8.46 | filing |
| 28 Jan 2025filed 30 Jan 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —411,000 at $0.00 | filing |
| 13 Aug 2024filed 14 Aug 2024 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,400 at $0.00 | filing |
| 13 Aug 2024filed 14 Aug 2024 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —194,600 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
News
Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Garry Arthur Neil; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.